|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
2003-12-19
|
|
pubmed:abstractText |
We studied the pharmacokinetics of amprenavir at doses of 600 mg twice a day or 1200 mg once a day, when co-administered to HIV-positive patients with 400 mg a day of atazanavir without a ritonavir booster. Our preliminary results suggest that amprenavir and atazanavir could be coadministered and that amprenavir could be boosted by atazanavir without the need for ritonavir pharmaco-enhancement.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0269-9370
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
5
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2669-71
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:14685066-Adult,
pubmed-meshheading:14685066-Carbamates,
pubmed-meshheading:14685066-Drug Administration Schedule,
pubmed-meshheading:14685066-Drug Therapy, Combination,
pubmed-meshheading:14685066-Female,
pubmed-meshheading:14685066-HIV Protease Inhibitors,
pubmed-meshheading:14685066-HIV Seropositivity,
pubmed-meshheading:14685066-Humans,
pubmed-meshheading:14685066-Male,
pubmed-meshheading:14685066-Middle Aged,
pubmed-meshheading:14685066-Oligopeptides,
pubmed-meshheading:14685066-Pilot Projects,
pubmed-meshheading:14685066-Pyridines,
pubmed-meshheading:14685066-Reverse Transcriptase Inhibitors,
pubmed-meshheading:14685066-Sulfonamides,
pubmed-meshheading:14685066-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients.
|
|
pubmed:affiliation |
Department of Infectious Diseases, Vita/Salute University, San Raffaele Scientific Institute, Milan, Italy.
|
|
pubmed:publicationType |
Journal Article
|
